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Christina M. Heyer,1 Katharina Hopp,1,5 Marie E. Edwards,1 Charles D. Madsen,1 Sarah R. Mauritz,1
Carly J. Banks,1 Saurabh Baheti,6 Bharathi Reddy,7 Jose´ Ignacio Herrero,8,9,10 Jesu´s M. Ban˜ales,11
Marie C. Hogan,1 Velibor Tasic,12 Terry J. Watnick,13 Arlene B. Chapman,7 Ce´cile Vigneau,14
Fre´de´ric Lavainne,15 Marie-Pierre Audre´zet,2 Claude Ferec,2 Yannick Le Meur,3 Vicente E. Torres,1
Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group, Consortium for
Radiologic Imaging Studies of Polycystic Kidney Disease, and Peter C. Harris1,4,*
Autosomal-dominant polycystic kidney disease (ADPKD) is a common, progressive, adult-onset disease that is an important cause of
end-stage renal disease (ESRD), which requires transplantation or dialysis. Mutations in PKD1 or PKD2 (~85% and ~15% of resolved
cases, respectively) are the known causes of ADPKD. Extrarenal manifestations include an increased level of intracranial aneurysms
and polycystic liver disease (PLD), which can be severe and associated with significant morbidity. Autosomal-dominant PLD (ADPLD)
with no or very few renal cysts is a separate disorder caused by PRKCSH, SEC63, or LRP5 mutations. After screening, 7%–10% of
ADPKD-affected and ~50% of ADPLD-affected families were genetically unresolved (GUR), suggesting further genetic heterogeneity
of both disorders. Whole-exome sequencing of six GUR ADPKD-affected families identified one with a missense mutation in GANAB,
encoding glucosidase II subunit a (GIIa). Because PRKCSH encodes GIIb, GANAB is a strong ADPKD and ADPLD candidate gene. Sanger
screening of 321 additional GUR families identified eight further likely mutations (six truncating), and a total of 20 affected individuals
were identified in seven ADPKD- and two ADPLD-affected families. The phenotype was mild PKD and variable, including severe, PLD.
Analysis of GANAB-null cells showed an absolute requirement of GIIa for maturation and surface and ciliary localization of the ADPKD
proteins (PC1 and PC2), and reducedmature PC1was seen inGANABþ/ cells. PC1 surface localization inGANAB/ cells was rescued by
wild-type, but not mutant, GIIa. Overall, we show that GANABmutations cause ADPKD and ADPLD and that the cystogenesis is most
likely driven by defects in PC1 maturation.Introduction
Autosomal-dominant polycystic kidney disease (ADPKD)
is one of the most common inherited disorders—it affects
~1/1,000 individuals worldwide—and is characterized by
progressive cyst development and expansion in the kid-
neys.1,2 In ~50% of affected individuals, ADPKD results
in end-stage renal disease (ESRD), and 4%–10% of ESRD
worldwide is due to ADPKD (see GeneReviews in Web
Resources). ADPKD is caused by mutations in PKD1
(MIM: 601313) or PKD2 (MIM: 173910) (~85% and ~15%
of mutation-resolved families, respectively).3–6 Genotype-
phenotype studies indicate an average age of 55.6 years
for ESRD associated with truncating PKD1 mutations,
67.9 years for non-truncating PKD1 mutations, and 79.7
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 2016 American Society of Human Genetics.613095]).7 Larger kidneys (measured by the height-
adjusted, MRI-determined total kidney volume [htTKV])
and an earlier decline in renal function (measured by
the estimated glomerular filtration rate [eGFR]) are also
associated with PKD1 (MIM: 173900).5,8 The PKD1- and
PKD2-associated proteins, polycystin 1 (PC1) and 2
(PC2), respectively, are membrane glycoproteins with
the primary cilium as a likely functional site.9 PC1 is
cleaved at the G-protein-coupled receptor proteolytic
site (GPS), and this cleavage is essential for its func-
tion.10,11 PC1 consists of two glycoforms of the N- and
C-terminal (NT and CT, respectively) GPS-cleaved prod-
ucts: (1) mature, endoglycosidase H (EndoH) resistant
(NTR and CTR) and (2) immature, EndoH sensitive (NTS
and CTS).12–14 The level of the mature glycoforms is
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with PC2 is critical for PC1 maturation and surface and
ciliary localization.12,15,16
In a number of comprehensive studies of the genes
mutated in ADPKD, 7%–10% of families are genetically
unresolved (GUR).5–7,17 The typical finding of mild kidney
disease in GUR cases5 suggests that few such families are
explained by missed, fully penetrant mutations at the
complex, segmentally duplicated PKD1 locus.3,18 However,
hypomorphic mutations at the existing loci—including
those due to mosaicism,19,20 phenocopies associated with
autosomal-dominant tubulointerstitial kidney disease
(ADTKD) loci,21,22 and phenotypic and screening mis-
takes—most likely explain some unlinked and GUR fam-
ilies.23 Nevertheless, additional genetic heterogeneity
seems possible.
Subjects affected by ADPKD have a ~53 higher risk of
developing intracranial aneurysms (ICAs).24 However,
polycystic liver disease (PLD) is the most frequent extra-
renal complication in ADPKD; a minority of mainly
females develop severe PLD that requires surgical interven-
tion.25,26 Unlike severe PKD, severe PLD is not associated
with a particular genic or PKD1 allelic type.25 Isolated,
autosomal-dominant PLD (ADPLD [MIM: 174050]) is a
separate inherited disorder where severe PLD can also
occur, but renal cysts are absent or very rare.27 ADPLD is
caused by mutations in PRKCSH (MIM: 177060), SEC63
(MIM: 608648), or LRP5.28–31 PRKCSH encodes the b sub-
unit of glucosidase II (GIIb);32,33 GII is an endoplasmic-
reticulum (ER)-resident enzyme that catalyzes hydrolysis
of the middle and innermost glucose residues of peptide-
bound oligosaccharides, and it triggers quality-control
assessment of glycoprotein folding through the calnexin
and calreticulin cycle.34–39 SEC63 facilitates the transloca-
tion of secreted or membrane proteins across the ER
membrane.40–43 Induced loss of Prkcsh or Sec63 in mouse
kidneys results in PKD, and an interactive PC1-PC2
network with PC1 as the rate-limiting component has
been proposed to maintain tubular differentiation.13 This
suggests that PRKCSH mutations might act through PC1
depletion, although PC2 reduction has also been noted
with Prkcsh depletion or loss.44,45 There is strong evidence
of further genetic heterogeneity in ADPLD, given that only
~50% of cases have been explained by the known genes
mutated in this disease.27,46
In this study, we employed global and focused screening
of GUR ADPKD- and ADPLD-affected families to identify a
gene mutated in these disorders. Characterization of cells
null for this gene links the pathogenesis to the maturation
and localization of PC1 and PC2.Subjects and Methods
Sample and Data Collection and Clinical Analysis
The relevant institutional review boards and ethics committees
approved all studies, and participants gave informed consent.
Blood samples for DNA isolation were collected from the proband1194 The American Journal of Human Genetics 98, 1193–1207, Juneand all available family members and were isolated by standard
methods by the Mayo Biospecimens Accessioning and Processing
Core or the Genkyst study. Clinical and imaging data were ob-
tained by review of clinical records. Total kidney volume (TKV)
and total liver volume (TLV) were measured from clinical MRI
and computed-tomography (CT) imaging at the Mayo Transla-
tional PKD Center, which employed the stereology method with
Analyze software or a semi-automated approach,47 and were
adjusted for height (htTKV or htTLV). Enlarged kidneys or livers
were defined as the mean þ 2 SDs of the normal htTKV or htTLV
adjusted for average height.26,48 Kidney function was calculated
from clinical serum creatinine measurements with the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
in adults49 and the Schwarz formula in the pediatric individual50
and expressed as mL/min/1.73 m2. Age at onset of high blood
pressure was defined as when the affected individual started anti-
hypertensive medication.Whole-Exome Sequencing and Bioinformatics
Analysis
Families were defined as GUR when no mutations were detected
from Sanger sequencing or multiplex ligation-dependent probe
amplification of PKD1 and PKD2. In addition, the Genkyst cohort,
including families PK20016, PK20017, and P1174, were screened
for HNF1B (MIM: 189907) mutations, and families with a possible
ADPLD diagnosis, including P1073, M472, and M656, were
screened for PRKCSH and SEC63 mutations.
Total genomic DNAwas quantified with a Qubit 2.0 fluorometer
(dsDNA BR Assay Kit, Thermo Fisher Scientific) and quality
checked with a NanoDrop. Subsequently, 250 ng or 1 mg of DNA
was sheared by sonication (Covaris E210, 150–200 bp) and puri-
fied by AMPure XP beads (Agencourt). The shearing efficiency
was checked on a Agilent Bioanalyzer 2100 (DNA1000 assay).
Whole-exome capture and Illumina library preparation were per-
formed with the Agilent SureSelectXT Human All Exon V5þUTRs
Kit on an Agilent Bravo workstation. The enriched library was
sequenced with 101 bp paired-end reads on an Illumina HiSeq
2000 in the Mayo Medical Genome Facility. On average, three
to four exomes per lane were multiplexed. Genome_GPS v.3.0.1
(Mayo Bioinformatics Core) was employed as a comprehensive
secondary analysis pipeline for variant calling. In short, FASTQ
files were aligned to the hg19 reference genome (UCSC Genome
Browser) with Novoalign (V2.08.01) with the options -hdrhd off
-v 120 -c 4 -i PE 425,80 -x 5 -r Random, and realignment and
recalibration were performed with the Genome Analysis Toolkit
(GATK) (3.3-0) Best Practices v.3 for each family separately. Over-
all, 75.6% of mapped reads aligned to the captured region, and
98.9% of the captured region was covered at 103 read depth.
Multi-sample variant calling was performed with the GATK
(3.3-0) Haplotype Caller, and variants were filtered with Variant
Quality Score Recalibration for both SNVs and indels. Variant
mining was performed with Golden Helix SNP & Variation Suite
v.8 (SVS). All families were analyzed independently with the
following filters: (1) quality filter of read depthR 103 and geno-
type qualityR 20, (2) selection according to autosomal-dominant
sample genotype pattern, (3) removal of Exome Aggregation
Consortium (ExAC) Browser variants with a minor allele fre-
quency > 0.1%, and (4) characterization of coding and non-cod-
ing SNVs within 14 bp of the splice site and subsequent removal
of SNPs predicted to be neutral by one or more of six dbNSFP
tools (SIFT, PolyPhen-2 HVAR, MutationTaster, Mutation Assessor,2, 2016
FATHMM, and FATHMM MKL) and dbscSNV (removal of SNVs
with Ada and RF scores < 0.6). Table S1 lists the variants that re-
mained after the SVS analysis.
Sanger Sequencing and Mutation Validation
Primers to amplify the 25 exons of GANAB (GenBank:
NM_198335.3), plus ~100 bp of flanking intervening sequences
(IVSs), were designed with MacVector 12.0.6, and 50 ng of
genomic DNA was used for PCR amplification (primers and PCR
conditions are available upon request). Sanger sequencing was
performed at Beckman Coulter Genomics according to standard
approaches, and variants were identified with Mutation Surveyor
software (SoftGenetics) and designated on the 25 exon GANAB
isoform and corresponding protein (GenBank: NP_938149.2).
When samples were available, segregation analysis was performed
by sequence analysis of the mutated exonic fragment. Amino acid
changes detected by Sanger sequencing were evaluated with the
programs SIFT and Align GVGD, and the atypical splicing change
in family M656 was evaluated with NNSPLICE 0.9 (Berkeley
Drosophila Genome Project). The families affected by GANABmu-
tations originate from the US (M263, M641, 290100, M656, and
M472), France (PK20016 and PK20017), Macedonia (P1174), and
Spain (P1073). One family came from the HALT Progression of
Polycystic Kidney Disease (HALT-PKD) cohort, two came from
Genkyst, and the remainder came from the Mayo PKD Center
population.
Using CRISPR/Cas9 to Generate Targeted
GANAB-Mutated Cell Lines
Guide RNAs predicted to have the lowest off-targeting effect were
cloned into pX330 (SpCas9) and verified by sequencing (see Table
S2 for sequences). GANAB ex11-IVS12 was amplified by PCR
(primer sequences are available on request), and the 550 bp
genomic product was cloned into pCAG-EGxxFP51 with restric-
tion sites BamHI and EcoRI. Each gRNA was then co-transfected
with p-CAG-EG-GANAB(11-IVS-12)-FP in renal cortical tubular
epithelial (RCTE) cells and scored after 24 hr for EGFP-positive
cells. gRNA4 was selected as the most efficient cutter and used
for generating cell lines. pX330-gRNA4 was transfected into
wild-type (WT) RCTE cells by electroporation, and the cells were
allowed to recover for 36 hr prior to splitting and re-seeding as sin-
gle-cell suspensions in a 96-well plate. Cells were grown for
10 days for the establishment of single clone cell colonies, split
in half, and re-seeded for screening. Screening was performed
with genomic DNA extraction followed by amplification using
GANAB ex11-IVS12 primers and a subsequent T7 mismatch assay.
For this assay, PCR amplicons were denatured at 95C for 2 min
and cooled gradually to 25C at a rate of 2C per second. The
reaction mixture was then subjected to T7 endonuclease (T7E1,
New England BioLabs) for 20 min at 37C and visualized in 2%
agarose gels. Clones were additionally screened by western blot-
ting (WB) for the a subunit of glucosidase II (GIIa) and Sanger
sequencing.
Generating FLAG-GIIa Constructs with Missense
Variants
C-terminal Myc-DDK-tagged GIIa (isoform 3 [GenBank:
NM_198335.3]) was obtained from OriGene. Missense mutations
were introduced by site-directed mutagenesis with Q5 high-fidel-
ity polymerase (New England BioLabs); primer sequences are
shown in Table S3.The AmericWB Studies, Glycosylation Analysis, and
Immunoprecipitation
For purification of crude membrane protein, cells were grown to
confluence, washed with Dulbecco’s PBS (DPBS), scraped and re-
constituted in LIS buffer (10 mM Tris HCl [pH 7.4], 2.5 mM
MgCl2, and 1mM EDTA) plus protease inhibitors (Complete,
Roche), and incubated on ice for 15 min. Homogenized total
membrane lysates were prepared by repeated passage through a
25.5G needle and centrifugation at 4,600 RPM for 5 min. All pro-
cedures employed pre-chilled containers and were performed in
the cold room to minimize protein loss to degradation. For immu-
noprecipitation (IP), the pellet of crudemembrane protein (75mg)
was solubilized in IP buffer, and samples were pre-cleared with
blank A/G agarose for 2 hr. Antibodies to the C terminus of PC1
(PC1-CT) or PC2 (YCE2) were added overnight and then incubated
with 50 mL of packed washed A/G Agarose (Thermo) for 2 hr. The
agarose was washed three times in IP buffer and once in ice-cold
H2O, and the protein was eluted in either lithium dodecyl sulfate
(LDS) plus tris(2-carboxyethyl)phosphine (TCEP) or agarose, split
into three equal parts (untreated, EndoH, and PNGaseF), and sub-
jected to deglycosylation analyses. Purifiedmembrane protein and
IP eluates were deglycosylated with EndoH and PNGaseF accord-
ing to the manufacturer’s (New England BioLabs) instructions.
Twenty-five micrograms of input and 100% of the IP were loaded
per SDS-PAGE lane.Surface Glycoprotein Labeling and
Immunoprecipitation
Surface glycoprotein labeling of living cells was performed as pre-
viously described.15 Monolayer cells in 10 cm culture dishes were
washed twice with ice-cold DPBS and then oxidized at 4C in
1 mM NaIO4 containing DPBS (pH 7) for 30 min, quenched
with ice-cold 1 mM glycerol in DPBS for 5 min, and washed twice
with ice-cold DPBS. Oxime ligation was performed in the presence
of 10 mM Aniline (Sigma-Aldrich) and 100 mM EZ-Link Alkoxy-
amine-PEG4-Biotin (Thermo Fisher Scientific) in 1% FBS supple-
mented with ice-cold DPBS buffer (pH 7.5) for 1 hr. Biotinylated
cells were then washed three times in PBS and scraped. Reaction
specificity was ensured with streptavidin-488 (Alexa Fluor) stain-
ing of a small sample of cells and visualized by fluorescent micro-
scopy. Scraped cells were collected by centrifugation, subjected to
purification of crude membrane protein, and solubilized in IP
buffer (20 mM HEPES [pH 7.5], 137 mM NaCl, 1% NP-40, 10%
(w/v) glycerol, 2 mM EDTA, and 2.5 mM MgCl2) supplemented
with protease inhibitors (Roche) for 15 min. Non-solubilized
proteinwas removed by centrifugation and discarded. Neutravidin
agarose was washed in IP buffer three times, and 50 mL of packed
agarose was added to solubilized membrane protein and agitated
at 4C for 2 hr. Samples were washed three times in IP buffer
and once in ice-cold H2O. Protein was eluted in either LDS plus
TCEP or agarose and subjected to deglycosylation analyses. Tris-ac-
etate gels were washed with ultrapure water and stained with the
ProteoSilver Silver Stain Kit (Sigma-Aldrich) according to the man-
ufacturer’s instructions.Transfection, Confocal Microscopy,
Immunofluorescence, and Surface PC1 Labeling
RCTE cells were split at a ratio of 1:2 the day before electroporation
and transfected at ~80% confluency. Electroporation of RCTE cells
was performed with the Bio-Rad Gene Pulser with a square-wave
protocol: 110V, 25 ms pulse and 0.2 cm cuvettes (Bio-Rad) inan Journal of Human Genetics 98, 1193–1207, June 2, 2016 1195
electroporation buffer (20 mMHEPES, 135 mMKCl, 2 mMMgCl2,
and 0.5% Ficoll 400 [pH 7.6]). TagGFP-PC2 andmCherry-PC1 used
in this study have been previously described.15 RCTE cells were
grown on glass coverslips, washed once with DPBS, fixed in
3.5% paraformaldehyde (PF) for 30 min, permeabilized with
0.1% Triton in DPBS (pH 7.5), washed again in PBS, and incubated
in blocking buffer (10% normal goat serum, 1% BSA, and 0.1%
Tween in PBS [pH 7.5]) for 30min. After three PBS washes, primary
antibodies were added to IF buffer (1% BSA, PBS [pH 7.5], and 0.1%
Tween) for 2 hr at room temperature or overnight at 4C with
gentle agitation. After three PBS washes, conjugated secondary
antibody (AlexaFluor, Invitrogen) was added for 1 hr. DAPI was
added for 1 min to stain nuclei.
For surface labeling of mCherry-PC1, transfected RCTE cells
were cooled at 4C for 15 min, washed once in ice-cold PBS and
pre-chilled mCherry antibody (BioVision), and incubated in
0.5% BSA in PBS for 30 min at 4C. Cells were then fixed in
3.5% PF, and conjugated secondary antibody was added to IF
buffer for 30 min. Confocal microscopy was performed with a
Zeiss Axiovert equipped with Apotome.
For pH shift and SDS IF, the fixation and antigen-retrieval
method was performed for visualizing endogenous PC2 in MEFs.
For partially denaturing the protein, cells were grown to 100%
confluency and serum starved for 48 hr, fixed in 3% PF (pH 7.5)
for 15 min, fixed in 4% PF (pH 11]) in 100 mM borate buffer for
15 min, and then permeabilized in 5% SDS for 5 min. Subse-
quently, PC2 antibody (H280) staining was performed overnight
at a 1:200 dilution at 4C as described above.Antibodies
The following antibodies were used: PC1-NT, 7e1252 (N-terminal,
mouse monoclonal; 1/1,000 for WB); PC1-CT, EB08670 (C-termi-
nal, goat; Everest Biotech; 1/250 for IP); PC2, H280 (rabbit; Santa
Cruz; 1/5,000 for WB and 1/200 for IF); PC2, YCE2 (mouse mono-
clonal; Santa Cruz; 1/2,000 forWB and 1/500 for IF); EGFR (rabbit;
BD Transduction labs; 1/1,000 for WB); acetylated a-tubulin
(Invitrogen; 1/5,000 for IF); mCherry, 5993-100 (rabbit; BioVision;
1/1,000 for surface labeling); FLAGM2 (Sigma; 1/1,000 for IF); and
GIIa, ab179805 (Abcam; 1/2,000 for WB).Results
WES Identifies GANAB as a Gene Mutated in ADPKD
After PKD1 and PKD2 mutation analysis for base-pair and
larger rearrangements, we identified 327 GUR families out
of ~3,600 screened. These GUR families originated from
the HALT-PKD cohort (64) (an ADPKD clinical trial) and
the Consortium for Radiologic Imaging Studies of Polycy-
stic Kidney Disease (CRISP) (16) and Genkyst (124) ADPKD
observational studies. In addition, 123 Mayo PKD Center
GUR families affected byADPKDormild renal cystic disease
and PLD were included. Although a firm clinical diagnosis
of ADPKD was made in 247 GUR pedigrees, in 80 pedigrees
the disease presentation was more atypical (cystic kidney
disease without kidney enlargement), although the vast
majority exceeded the defined ultrasound or MRI criteria
for an ADPKD diagnosis.53,54 In the seven remaining fam-
ilies, the disease presentation was more consistent with
ADPLD, although all but one had some renal cysts. PRKCSH1196 The American Journal of Human Genetics 98, 1193–1207, Juneand SEC63 screening was also performed in these families
before inclusion. Six multiplex GUR ADPKD-affected fam-
ilies were screened by WES, and standard screening
methods were employed to identify mutated, dominant
genes (see Subjects and Methods); the detected genes and
variants are listed in Table S1. A missed PKD1 mutation
was identified in one family (M560).
From this WES analysis, one candidate gene, GANAB,
encoding the catalytic subunit of glucosidase II (GIIa), ap-
peared most promising given that PRKCSH encodes the
non-catalytic b subunit of this enzyme, and mutations in
this gene cause ADPLD. GANAB (in chromosomal region
11q12.3; genomic size 21.9 kb) has two splice forms shown
by in silico and RT-PCR analysis to be approximately
equally expressed in the human kidneys and liver
(Figure S1): isoform 3 (GenBank: NM_198335.3) has 966
aa (~110 kDa), 25 exons, and 2,898 bp of coding sequence,
and isoform 2 (GenBank: NM_198334.2) has 944 aa
(~107 kDa), 24 exons (in-frame skipping of exon 6), and
2,832 bp of coding sequence.36,38 We employed the larger
splice form for mutation screening and designation and
functional studies. ExAC Browser exome data (60,706 indi-
viduals) list five loss-of-function (LoF) GANAB mutations
out of an expected 49.7 (probability of LoF intolerance
[pLI] ¼ 1.0; see Subjects and Methods), a figure similar to
that for PKD2 (7/37.6; pLI ¼ 1.0) and consistent with
GANABmutations’ causing dominant disease.55,56
TheGANABmissense variant, c.1265G>T (p.Arg422Leu),
was detected by WES in family M263 and found in the
affected father and daughter, but not the unaffected
daughter (Figures 1A–1C). In silico analysis, including
conservation in multi-sequence alignments (MSAs) of pro-
teins orthologous to yeast and related glucosidases showed
that this variant is highly predicted to be pathogenic (Fig-
ures 1D and 1E). Both of the affected individuals had mild
kidney and significant liver cystic disease (Figures 1F and
1G and Table 1).
Identification of Further ADPKD-Affected Families
with GANAB Mutations
Given that mutations in GANABmight account for disease
in families with unresolved ADPKD, we analyzed our re-
maining GUR cohort of 321 families by Sanger sequencing
of the coding region. From this analysis, we identified eight
additional families affected by GANAB mutations: three
frameshift, two splicing, one nonsense, and two missense
mutations (Table 1). Data from the ExAC Browser showed
that none of the GANAB variants, except c.152_153delGA
(reported once), have been reported in the 60,706 unre-
lated individuals sequenced as part of various disease-spe-
cific and population genetic studies.55 Additionally, none
of these variants were seen in the NHLBI Exome Sequence
Project (ESP) Exome Variant Server.
The GANAB frameshift mutation, c.1914_1915delAG
(p.Asp640Glnfs*77), was found in two families, M641
and 290100 (Figures 2A–2E, Figures S2A, S2B, and S3A,
and Table 1). In M641, two sisters had relatively mild2, 2016
Figure 1. WES Analysis Reveals GIIa p.Arg422Leu (c.1265G>T) in Family M263 as the Likely Pathogenic Variant
(A) Pedigree of family M263 shows that the two affected individuals (I-1 and II-1, shaded in black) have the GIIa p.Arg422Leu (p.R422L)
missense variant resulting from c.1256G>T in exon 12, but the unaffected daughter (II-2, for whom no cysts were detected on ultra-
sound at 30 years of age) does not.
(B) GenomeBrowse (SVS, GoldenHelix) view of theWES results from II-1 showGANAB variant c.1265G>T (reverse strand), and details of
the reads are tabulated below.
(C) Sanger sequencing confirmation of heterozygous GIIa variant p.Arg422Leu (p.R422L) (c.1256G>T) in II-1. The WT is shown for
comparison.
(D) MSA of GIIa orthologous proteins shows invariance of Arg422 from humans to yeast. In silico analysis of the likely pathogenicity of
GIIa p.Arg422Leu (p.R422L) shows variant scores (SIFT ¼ 0.00, Align GVGD ¼ C65) characteristic of a highly likely pathogenic
mutation.
(E) MSA of related glucosidases GANC (neutral alpha-glucosidase C) and GAA (lysosomal alpha-glucosidase) of various eukaryotic species
and prokaryotic GH31 (glycosyl hydrolase family 31) shows invariant conservation of GIIa Arg422.
(F) CT scan with contrast of kidneys and liver of individual I-1 at 66 years shows a few large kidney cysts (red arrows) and multiple scat-
tered liver cysts (green arrows).
(G) T2-weighted MRI of II-1 at 41 years shows a few kidney (red arrows) and liver (green arrows) cysts.PKD with variable liver cysts. The family history was un-
clear: the father died at 75 years with renal cell cancer
but no reported cysts, and there was no information on
the mother. Both sisters had ICAs (see the Figure 2 legend
for details), and the father was reported to have a ruptured
aneurysm. In family 290100, the father and son both had
mild PKD, and multiple liver cysts were present in the fa-
ther, but not the son.The AmericIn family P1174, the GANAB missense variant,
c.1214C>G (p.Thr405Arg), was found in three genera-
tions, including in individual III-1, in whom renal cysts
were detected incidentally in infancy (Figures 2F–2H, Fig-
ures S2C and S3B, and Table 1). The substituted residue is
invariant in orthologs and conserved in related proteins
(Figures 2I and 2J). The GANAB splicing mutation,
c.2690þ2_þ7del, was found in four affected familyan Journal of Human Genetics 98, 1193–1207, June 2, 2016 1197
Table 1. Clinical Presentation of Kidney and Liver Disease in the 20 Affected Individuals from Nine Families with GANAB Mutations
Family GANAB Mutation Subject Sex
eGFRa (Age
in Years)
HBP (Age
in Yearsb)
Radiologic Presentation
Kidneys Liver
Type Agec Cysts Volumed Figure Cysts Volumee Figure
M263f c.1265G>T
(p.Arg422Leu)
I-1 M 78 (66) N (67) CT 66 ~10 bilateral cysts
(largest 11 cm)
302g 1F >50 scattered cysts
(largest 6 cm)
1,226 1F
II-1 F 91 (42) N (43) MRI 41 ~10 bilateral cysts
(largest 3 cm)
211 1G >20 scattered cysts
(largest 3 cm)
835 1G
M641 c.1914_1915delAG
(p.Asp640Glnfs*77)
II-1 F 86 (51) Y (40) CT 55 ~15 bilateral cysts
(largest 10 cm)
822g S3A no liver cysts detected 1,505h S3A
II-2 F 104 (46) N (50) CT 45 ~10 bilateral cysts
(largest 6 cm)
318g 2B ~20 scattered cysts
(largest 2 cm)
764 2B
290100 c.1914_1915delAG
(p.Asp640Glnfs*77)
I-1 M 78 (65) N (65) MRI 58 ~8 bilateral cysts
(largest 2 cm)
227 2E >30 scattered cysts
(largest 3 cm)
1,255 2E
II-1 M 87 (25) Y (13) MRI 24 ~12 bilateral cysts
(largest 2.5 cm)
259 2D none 832 2D
P1174 c.1214C>G
(p.Thr405Arg)
I-1 M NAi N (61) US 55 3 cysts in the left
kidney
NE S3B 1 cyst (1.5 cm) NE –
II-1 F NAi N (35) US 29 2 cysts in the right
kidney
NE 2H NA NA –
III-1 M 122 (9) N (9) MRI 9 ~5 bilateral cysts
(largest 2 cm)
116 2G none 492 –
M656 c.2690þ2_þ7del I-1 M NAi Y (55) CT* 67 multiple small cysts NE S3C none NE S3C
II-1 M 84 (39) N (39) US 44 multiple cysts
reported
NA – multiple cysts
reported
NA –
II-2 F 77 (50) N (50) US 52 ~5–10 bilateral cysts
(largest 2 cm)
NE S3D >20 scattered cysts
(largest 5 cm)
NE S3D
II-3 M 95 (49) Y (35) MRI 43 >30 bilateral cysts
(largest 3 cm)
SE 2L >20 scattered cysts
(largest 1 cm)
NE 2L
PK20016 c.391G>C II-1 M 90 (53) Y (45) CT* 52 ~20 bilateral cysts
(largest 10 cm)
665g 3B ~20 scattered cysts
(largest 2 cm)
1,449h 3B
PK20017 c.2176C>T
(p.Arg726*)
II-1 F 77 (78) Y (53) US 78 ~40 bilateral cysts
(largest 3 cm)
NE 3D ~20 scattered cysts
(largest 1.5 cm)
NA 3D
P1073 c.2515C>T
(p.Arg839Trp)
I-2 F NA NA US (78) unknown NA – multiple cysts
reported
NA –
II-1 F 86 (50) N CT* 43 ~8 bilateral cysts
(largest 1 cm)
196 3F severe PLD, transplant
at 43 years
4,641h 3F
II-2 M NA NA US (44) unknown NA – multiple cysts
reported
NA –
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The Americmembers in M656 (Figures 2K and 2L, Figures S2D, S3C,
and S3D, and Table 1). All members (apart from II-3, who
had multiple kidney cysts) had no to mild cystic liver dis-
ease andmild kidney disease. Of note, themother (without
theGANABmutation) hadmultiple cysts of unresolved eti-
ology. PK20016 had the splicing mutation c.391G>C,
and PK20017 had the nonsense mutation c.2176C>T
(p.Arg726*), and both had only one known affected family
member (Figures 3A–3D, Figures S2E and S2F, Table 1).
Both individuals had multiple kidney cysts and a few
liver cysts.
Identification of Families Affected by GANAB
Mutations and ADPLD
Unlike the described ADPKD-affected families, families
P1073 and M472 had a possible diagnosis of ADPLD,
although a few renal cysts were present. P1073 had the
missense mutation c.2515C>T (p.Arg839Trp), which is
at an invariant site in orthologs and segregates in three
affected family members (Figures 3E–3G, Figure S2G,
and Table 1). As indicated, there were very few renal
cysts but multiple liver cysts, and the daughter (II-1)
required a liver transplant at 43 years. M472 individual
II-1, who had the GANAB frameshift mutation c.152_
153delGA (p.Arg51Lysfs*21) (Figures 3H and 3I, Fig-
ure S2H, and Table 1), had a few small kidney cysts but
severe PLD that required partial liver resections.
A similar phenotype with less severe PLD was seen in
II-2 (Figure S3E), although a sample was unavailable for
mutation analysis.
Characterization of the Effect of GANAB Loss on PC1
and PC2 Maturation and Localization
From the genetic studies, mutations in GANAB were
shown to be a cause of ADPKD and ADPLD, so we next
explored the mechanism of pathogenesis by cellular anal-
ysis. CRISPR/Cas9 targeting of GANAB exon 12 in human
RCTE cells generated clones with biallelic frameshift
mutations (null; clone C6) or a single in-frame deletion
(heterozygous; E4) (Figures S4A–S4D). Analysis of the
polycystin complex immunocaptured with PC2 or PC1-
CT antibodies in GANAB/ cells showed that the PC1
N-terminal, mature product (PC1-NTR) was absent (Fig-
ures 4A and 4B). In contrast, full-length (GPS-uncleaved)
PC1, PC1-NTS, and PC2 were elevated, indicating that
GIIa plays a major role in PC1 maturation. We previously
showed an interdependence of PC1 and PC2 for localiza-
tion, including to cilia,15 and so to assess localization
of the polycystin complex, we analyzed PC2. Ciliary
localization of PC2 was completely absent in GANAB/
cells, although cilia formed normally (Figure 4C and
Figure S4E).15,16 Given that affected individuals harbored
just one GANAB mutation, we assayed GANABþ/ cells
and found a proportional, ~50%, depletion of PC1-NTR
(Figures 4D and 4E). Analysis of the maturation of other
membrane proteins (epidermal growth factor receptor
[EGFR] and E-cadherin) showed that they were notan Journal of Human Genetics 98, 1193–1207, June 2, 2016 1199
Figure 2. Characterization ofGANABMu-
tations in Four ADPKD-Affected Families
(A) Pedigree of family M641 shows
c.1914_1915delAG (p.Asp640Glnfs*77)
(exon 17) in two affected siblings. Both sis-
ters had basilar tip aneurysms, and II-2 also
had two aneurysms detected on the left
middle cerebral artery. The affected status
of the parents is unclear (gray shading);
I-1 had renal cell carcinoma and a ruptured
aneurysm, but no reported PKD.
(B) CT scan of kidneys and liver from II-2
showsmultiple kidney and occasional liver
cysts.
(C) Pedigree of family 290100 shows
c.1914_1915delAG in the father and son.
(D and E) MRI shows a few kidney but no
hepatic cysts in II-1 (D) and a few kidney
and scattered liver cysts in I-1 (E).
(F) Pedigree of family P1174 shows
p.Thr405Arg (p.T405R) (c.1214C>G, exon
11) in three affected individuals; III-2,
for whom no cysts were detected by ultra-
sound at 5 years, did not have the variant.
(G and H) MRI of III-1 shows bilateral
kidney cysts (G), and ultrasound (US) of
II-1 shows a single large renal cyst (H).
(I) MSA of GIIa orthologs shows that
Thr405 is invariant across species. In
silico mutation analysis highly predicts
p.Thr405Arg (p.T405R) to be pathogenic
(SIFT ¼ 0.00, Align GVGD ¼ C65).
(J) MSA of GANAB-like proteins shows
invariant conservation of this residue.
(K) Pedigree of family M656 shows
c.2690þ2_þ7del (IVS20) in four affected
members. Splicing predictions show com-
plete loss of the donor site. The mother
(I-2), who does not have the GANABmuta-
tion, has ~5 kidney and ~30 liver cysts,
but no detected PKD1, PKD2, PRKCSH, or
SEC63 mutations.
(L) MRI of II-3 shows small hepatic and-
multiple renal cysts. Red and green arrows
indicate kidney and liver cysts, respec-
tively. Where multiple cysts are present,
only representative cysts are highlighted.(or only mildly) affected by loss of GIIa (Figure 4A).
Further analysis of terminally glycosylated proteins in
GANAB/ cells did not suggest a global disruption of sur-
face-localized proteins (Figures S4F–S4H).
Functional Analysis of GANAB Mutations and
Variants
To determine the effect of GANAB loss on PC1 localization
by immunofluorescence and to test the pathogenicity
of detected GIIa variants, we co-transfected WT and
GANAB/ cells with tagged PC1 and PC2 constructs
(mCherry-PC1-V5 and GFP-PC2; Figures 5A and 5B).151200 The American Journal of Human Genetics 98, 1193–1207, June 2, 2016GIIa loss prevented efficient surface
localization of tagged PC1, which
was restored by co-expression of WT
FLAG-GIIa (Figure 5A). IdentifiedGIIa missense variants (p.Thr405Arg, p.Arg422Leu, and
p.Arg839Trp), expressed as FLAG-GIIa constructs, failed
to rescue PC1 surface localization in GANAB/ cells
(Figure 5A), whereas three other variants considered likely
to be neutral (c.284A>G [p.Gln95Arg], c.760A>G
[p.Thr254Ala], and c.991C>T [p.Arg331Cys]) restored sur-
face localization (Figure S5).
Discussion
The combination of the human genetic studies and
cellular analysis of GANAB-null cells showed that
Figure 3. Characterization of GANAB
Variants in Four Families, Including
ADPLD-Affected P1073 and M472
(A) Pedigree of family PK20016 shows the
splicing mutation c.391G>C (IVS1). The
family history is unclear because samples
were unavailable, but one large renal cyst
was reported in I-1.
(B) CT scan of II-1 shows bilateral kidney
cysts and occasional hepatic cysts.
(C) Pedigree of family PK20017 shows
p.Arg726* (p.R726*) (c.2176C>T, exon
18), in the proband, II-1. A lack of DNA
samples and clinical information pre-
cluded determining the family history.
II-2 died at 55 years from a ruptured intra-
cranial aneurysm, but his PKD status was
unknown.
(D) Ultrasound examination of II-1 shows
several liver (left), and kidney cysts (right).
(E) Pedigree of family P1073 shows
p.Arg839Trp (p.R839W) (c.2515C>T,
exon 22) in three affected individuals.
(F) CT scan of II-1 shows very few kidney
cysts (left) but severe PLD (right). Gross
images of the liver of this subject have
been published.57
(G) MSA of GANAB (GIIa) orthologs shows
invariant conservation of Arg839 across
species. In silico mutation analysis highly
predicts p.Arg839Trp (p.R839W) to be
pathogenic (SIFT ¼ 0.00, Align GVGD ¼
C65).
(H) Pedigree of family M472 shows
c.152_153delGA (p.Arg51Lysfs*21)
(p.R51fs; exon 3) in II-1.
(I) MRI of II-1 shows a few renal cysts (left)
but significant PLD; this image was subse-
quent to earlier resections (Table 1). No
sample was available from II-2, but im-
aging also showed predominant PLD
(Figure S3E). Unavailable parental DNA
samples and limited clinical information
precluded determining the family history,
but I-1 was reported to have had a cerebral
hemorrhage. Red and green arrows indi-
cate kidney and liver cysts, respectively.
Where multiple cysts are present, only
representative cysts are highlighted.mutations in GANAB cause ADPKD and ADPLD, that loss
or reduction of GIIa is associated with maturation and
localization defects of PC1 and PC2, and that the identified
mutations cannot rescue the PC1 localization defect.
The renal phenotype associated with GANAB mutations
is consistently mild without renal insufficiency, such that
any kidney enlargement is due to a few large cysts. The
phenotype caused by GANAB mutations is more similar
to PKD2 than to PKD1 but is apparently even milder.58The American Journal of Human GOne individual had more severe PKD
(M656 member II-3), and here an un-
determined cystogenic influence from
the mother might be significant.
Applying imaging diagnostic criteria
developed in PKD1- and PKD2-affected families53,54 might be unreliable in families
affected by GANAB mutations even in those with a largely
renal phenotype given the disease mildness and the vari-
ability within families. The significance of the vascular
disease, noted in families M641, PK20017, and M472, is
presently unclear. Only in M641 do the definitely affected
sisters have ICAs; the vascular phenotypes in three other
individuals in these families are not proven to be linked
to GANAB mutations.enetics 98, 1193–1207, June 2, 2016 1201
Figure 4. GIIa Is Required for PC1 ER Exit and Maturation
(A) Deglycosylation analysis of WT and GANAB/ RCTE membrane protein either untreated (Un) or treated with EndoH (þE) or
PNGaseF (þP). IP was used to enrich the PC1 complex with C-terminal PC1 (PC1-CT) or PC2 (YCE2) antibodies and immunodetected
with the N-terminal PC1 (PC1-NT) antibody (7e12). Complete loss of the mature PC1 glycoform15 (NTR; red arrow) was observed
in GANAB/ cells, and full-length PC1 (FL) and PC1-NTS became more abundant. Mature E-cadherin and EGFR were not or only
marginally affected by GANAB loss; the EndoH-resistant protein (R, red arrow) persisted. No EndoH-resistant form of PC2 was
noted,15 but the protein was upregulated in GANAB/ cells. Loss of WT GIIa was confirmed in GANAB/ cells with the use of a C-ter-
minal antibody.
(B) Schematic representation of the observed PC1 banding pattern in the WT and GANAB/ cells shown in (A).
(C) Confocal z stack rendering of primary cilia in confluent WT and GANAB/ cells in which acetylated a-tubulin (Ac.a-tub) and PC2
were detected shows no cilia PC2 signal in GANAB/ cells. Nuclei were stained with DAPI, and 100 ciliated cells were analyzed in three
independent experiments. The scale bar represents 10 mm.
(D) Immunoblot of PC1-NT in WT and GANABþ/ cells shows a reduced level of PC1-NTR in GANABþ/ cells. Asterisks indicate a non-
specific product.15
(E) Quantification of PC1-NTR shows a reduction to ~50% (p < 0.001, Student’s t test) in heterozygous cells and a complete loss in
homozygous, GANAB/ cells.The liver disease is variable and ranges from no cysts to
severe PLD requiring surgical intervention. The highly
variable PLD phenotype is characteristic of ADPKD and
ADPLD. Allelic effects do not appear to explain this
variability, although some evidence of familial clustering
of severe PLD suggests that genetic modifiers play a signif-
icant role.25,46 It is interesting that GANABmutations were
identified as the cause of the disease in two of the seven
ADPLD-affected families studied, suggesting that the mu-
tation-detection rate might be higher in ADPLD-affected
families. Although there might be ascertainment bias
because ADPKD was the diagnosis in the vast majority of1202 The American Journal of Human Genetics 98, 1193–1207, Junescreened families, the overall phenotype appears to
involve more renal disease than described in PRKCSH.59
The reason for this is unclear given that they are subunits
of the same protein, and further analysis of GANAB in
ADPLD and PRKCSH in ADPKD populations is required.
We show that phenotypes consistent with mild ADPKD
and ADPLD involving a few renal cysts can be caused by
GANAB mutations. Rather than considering ADPKD and
ADPLD to be strictly separate diseases, we suggest
recording the full range of phenotypes associated with
each gene in which mutations are associated with ADPKD
and/or ADPLD.2, 2016
Figure 5. Surface Localization of PC1 Requires WT GIIa and Is Disrupted by GANABMissense Mutations
(A)WTandGANAB/ cells were co-transfected withWT tagged PC1 and PC2, mCherry-PC1, and TagGFP-PC2 and examined for surface
mCherry-PC1 labeling. Co-transfected cells were screened for live cell-surface PC1 signal and quantified as the percentage of surface-pos-
itive PC1 cells out of the total co-transfected cells. Surface PC1 was detected on 55.0% 5 6.8% of WT cells but only 5.9% 5 2.0% of
GANAB/ cells (p% 0.0001), and the level was rescued to 32.7%5 4.9% by co-transfection with the WT GANAB (FLAG-GIIa) plasmid.
Co-transfection with the newly identified putative GANAB missense mutations cloned in FLAG-GIIa, p.Thr405Arg (p.T405R),
p.Arg422Leu (p.R422L), and p.Arg839Trp (p.R839W) did not rescue PC1 surface localization (bottom three panels; all p < 0.0001 versus
WT rescue). Student’s t test was performed to determine significance in at least 100 triple-transfected cells analyzed among three inde-
pendent experiments. The scale bar represents 20 mm.
(B) Diagram of the constructs.GANAB mutations account for ~3% of GUR ADPKD-
affected families (~0.3% total ADPKD), although given
that many GUR cases most likely involve PKD1 or PKD2
mutations that were missed (see Introduction and Paul
et al.23), they are probably responsible for a much greater
proportion of missing genetic causes of ADPKD. In addi-
tion, because of the mild phenotype, these mutations are
most likely underdiagnosed and, in particular, might
be more common in families with mild PKD and signifi-
cant PLD.
Defects inglycosylation andprotein traffickingunderlie a
large number of human diseases,60,61 but the interesting
aspect here is the specificity of the phenotype associated
with disruption of a step in a process important for manyThe Americproteins. GII functions in the early cargo-recruitment steps
of the calnexin and calreticulin cycle, which facilitates
the quality control and maturation of transmembrane
glycoproteins.34 GANAB/ cells and S. pombemutants are
viable without growth defects,62,63 and we have demon-
strated a lack of global, surface glycoprotein deficiencies
in GANAB/ cells, which suggests that endomannosidase
activity and other chaperones and folding-assisting pro-
teins can generally compensate for this loss, at least in
non-stress conditions. The complexity due to protein size
and extensive N-linked glycosylation might underlie the
critical dependence of PC1 onGII and the calnexin and cal-
reticulin cycle for achievingnative folding.At this stage, it is
unclear whether the enrichment of PLD associatedwithGIIan Journal of Human Genetics 98, 1193–1207, June 2, 2016 1203
deficiency indicates that the liver is particularly vulnerable
to reduction of this enzyme. In contrast to that described
for SEC63 deficiency,15,62,64,65 the defect we observed in
GANAB/ cells was complete disruption of PC1 matura-
tion, which increased ER accumulation of cleaved PC1
while onlymarginally affectingGPS cleavage. InRCTEcells,
GANAB heterozygosity was associated with a ~50% reduc-
tion of PC1-NTR, a level predisposing to cyst development
in association with stochastic, renal injury and/or somatic
events.12,15,66,67 However, fully understanding quantita-
tively how PC1 maturation is influenced by GII dosage
will require further studies, which could provide insights
into a therapeutic role for cellular and molecular chaper-
ones in ADPKD.Accession Numbers
The accession number for the cDNA sequence reported in this
paper is GenBank: NM_198335.3.Supplemental Data
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